Study: Middle-aged people who sleep less than than 7 hours nightly may have increased risk of dementia
By Catherine Park
A new study shows that people with dementia are at an increased risk of contracting COVID-19.
Middle-aged people who get less than seven hours of sleep a night could be at higher risk for developing dementia later in life, according to a recent study.
The study, highlighted by the National Institute of Health, was led by Dr. Séverine Sabia of Inserm and University College London and published in Nature Communications on April 20, followed participants for less than a decade who were in their 50s, 60s and 70s.
(1)
Collaborative mice study with UC San Diego to study brain development from embryo to old age
Berwyn, Pennsylvania (Newsfile Corp. - April 29, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer s disease (AD), Parkinson s disease (PD) and other neurodegenerative diseases, today announced a new research collaboration with Professor William Mobley and Dr. Xuqiao Chen at the University of California San Diego designed to study the ability of the Company s lead compound, ANVS401, to normalize brain development in Down Syndrome (DS) mice. While we know quite a bit about how the brain degenerates in the later stages of life, extraordinarily little is known about how neurodegeneration may start very early in life. We, therefore, plan to look at the brain in embryonic development in DS mice, said Maria Maccecchini, Ph.D., Founder and Chief Executive Officer.
Researchers assess the theoretical impact of biomarker framework on dementia prediction
One of the biggest challenges in Alzheimer s research is to identify biomarkers that can identify people who are at risk of developing dementia. Biomarkers could be used to screen people so they might be helped before they develop dementia.
Researchers have focused primarily on three such biomarkers. Two are Alzheimer s-related proteins, amyloid and tau. Amyloid forms clumps in brains, and tau forms skeins of filaments called neurofibrillary tangles. Both can be detected in cerebral spinal fluid or by specialized positron emission tomography (PET) scans. The third marker, brain atrophy, can be seen with CT or MRI scans.
E-Mail
IMAGE: An image taken from a normal brain is shown on the left. Dilation of the ventricles (arrow) in the brain image on the right is a sign of atrophy that. view more
Credit: Adult Changes in Thought (ACT) study team
One of the biggest challenges in Alzheimer s research is to identify biomarkers that can identify people who are at risk of developing dementia. Biomarkers could be used to screen people so they might be helped before they develop dementia.
Researchers have focused primarily on three such biomarkers. Two are Alzheimer s-related proteins, amyloid and tau. Amyloid forms clumps in brains, and tau forms skeins of filaments called neurofibrillary tangles. Both can be detected in cerebral spinal fluid or by specialized positron emission tomography (PET) scans. The third marker, brain atrophy, can be seen with CT or MRI scans.
Today
Cloudy with snow showers mainly during the evening. Low 28F. Winds E at 5 to 10 mph. Chance of snow 70%..
Tonight
Cloudy with snow showers mainly during the evening. Low 28F. Winds E at 5 to 10 mph. Chance of snow 70%. Updated: April 13, 2021 @ 7:35 pm